

	Explanation	Screened range	Default
$N$	Number of beds	-	20
$t_{LOS}$	Length of stay for asymptomatic patients [days]	2, 5, 7, 10, 15, 20, 50	7 days*
$r_I$	Retention of infected patients (i.e. factor by which discharge of infected is more or less likely than for asymptomatic patients; low values indicate symptomatic infected are more likely to be removed, e.g. isolation; high values indicate symptomatic patients remain very likely in hospital)	0.5, 1, 3, 5, 10, 20, 50	3**
$t_e$	Half-life of pathogens in reservoir [days]	1, 2, 5, 10, 20, 30, 50	20 days [73]
$\chi$	Rate of environmental contamination	-	0.1***

	Explanation	Screened range	Default
$p_P$	Proportion protecteds among incoming patients [%]	0, 15, 30, 45, 60, 75, 90	0%
$p_S$	Proportion patients that are not fully protected by microflora [%]	0, 20, 40, 60, 80, 95, 99	20%
$f_i$	Proportion of incoming carriers that are symptomatic [%]	0, 5, 20, 40, 60, 80, 100	5% (i.e. 0.25% of admitted patients symptomatic carriers)
$f_{res}$	Fraction of carriers (C +I) carrying strains resistant to either A, B or AB [%]	0, 10, 20, 40, 60, 80, 100	scenario i: 0% scenario ii and iii: 10% (i.e. 2% of admitted patients are carriers of a resistant strain)[74]
$p_{asym}$	Asymmetry of A- and B-resistance among incoming patients (low values indicate all B- or AB-resistant; high values indicate all A- or AB- resistant) [%]	0, 20, 40, 50, 60, 80, 100	50% (as many A- as B-resistant)
$f_{double}$	Fraction double-resistance of all resistant strains (low values indicate only single-resistances; high values indicate only double-resistance) [%]	0, 20, 40, 50, 60, 80, 100	scenario i and ii: 0% scenario iii: 40% (i.e. 0.8% of admitted patients are carriers of a double resistant strain)[74]

	Explanation	Screened range	Default
$c_a$	cost of resistance A [%]	0, 10, 20, 30, 40, 50, 60	10% [75-77]
$c_b$	cost of resistance B [%]	0, 10, 20, 30, 40, 50, 60	10% [75-77]
$c_{ab}$	cost of resistance AB [%]	0, 10, 20, 30, 40, 50, 60	20% [75-77]
$t_{cl,P}$	Time until protection by microflora is gone when treated with broadspectrum	-	-
$t_{cl}$	Time until carrier is not infectious when appropriately treated [days]	1, 2, 5, 7, 10, 15, 20	5 days [78, 79]
$\mu_a$	Frequency of new A-resistance mutation per patient day	$10^{-1}, 10^{-2}, 10^{-3}, 10^{-4}, 10^{-5}, 10^{-6}, 10^{-7}$	$10^{-4}$ (both A and B equally likely)
$\mu_a/\mu_b$	Relative frequency of new B-resistance mutations per day	$10^{-2}, 10^{-1}, 1, 10, 10^2, 10^4, 10^6$	1 (both A and B equally likely)
$\mu_{ab}/(\mu_a * \mu_b)$	Relative frequency of new AB-resistance mutations per day	$10^{-3}, 10^{-2}, 10^{-1}, 1, 10, 10^2, 10^3$	1 (both A and B mutations independent)
$d$	Time to death if untreated [days]	2, 5, 10, 20, 30, 50, 100	7 days
$t_P$	Time to progression from colonized to infected [days]	1, 5, 7, 10, 20, 50, never	7 days (this corresponds to ~8% of patients acquiring an infection in the hospital, which is global average) [1]
$\beta_D$	Infectious encounters between patients resulting in colonization per patient day (calculated for 20 beds)	0.005, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035	0.02 [22, 23] ( $R_0$ of wild-type $\approx 1.5$ , $R_A$ , the number of secondary infections in a hospital is $\sim 0.4$ , because we assume that there is no superinfection and hence only a fraction of the patients is susceptible)*
$\beta_E/\beta_D$	Infectious encounters with environment resulting in coloni-zation per patient day (calculated for 20 beds) relative to $\beta_D$	0, 0.17, 0.33, 0.50, 0.67, 0.83, 1	Equivalent to $\beta_D/t_e\chi$ (adjusted such that for any given environmental decay rate $t_e$ , $R_0$ of environmental transmission is equal to the $R_0$ for direct transmission in the same scenario)

	Explanation	Screened range	Default
$t_s$	Rate with which inappropriate treatment of infected patients is switched from A to B or B to A. This is not the same as colonized patients progressing to symptomatic disease, in which case we always assume that treatment is switched within a day	never, 0.17, 0.33, 0.50, 0.67, 0.83, 1	never
$f_P$	fraction of asymptomatic patients receiving scheduled treatment for prophylaxis or treatment of other disease [%]	0, 5, 10, 15, 20, 30, 40	20%
$f_{p,AB}$	fraction of asymptomatic patients additionally receiving both drug A and B for prophylaxis or treatment of other disease [%]	0, 1, 5, 10, 20, 50, 100	1%